Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zegocractin - CalciMedica

Next Previous
Drug Profile

Zegocractin - CalciMedica

Alternative Names: Auxora; CM-4620; CM4620-IE

Latest Information Update: 18 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CalciMedica
  • Class Anti-inflammatories; Antivirals; Benzamides; Chlorobenzenes; Dioxoles; Fluorobenzenes; Pyrazines; Small molecules
  • Mechanism of Action Immunosuppressants; ORAI1 protein inhibitors; STIM1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III COVID-19 pneumonia
  • Phase II Pancreatitis; SARS-CoV-2 acute respiratory disease; Systemic inflammatory response syndrome
  • Preclinical Acute kidney injury; Inflammatory bowel diseases; Renal failure; Respiratory distress syndrome

Most Recent Events

  • 13 Mar 2024 Pharmacodynamics data from preclinical studies in Acute kidney injury released by CalciMedica
  • 28 Feb 2024 Preclinical trials in Acute kidney injury in USA (IV) prior to February 2024
  • 28 Feb 2024 Pharmacodynamics data from a preclinical studies in Acute kidney injury released by CalciMedica
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top